Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.35 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
| ▸ | CES1 | P23141 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ERN1 | O75460 | 1/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17748457 | 0.84 | RAPGEF4 (0.42) | ALDH1A1RAPGEF4EGFRLMNAERN1 | |
| SCHEMBL18860247 | 0.81 | HDAC3 (0.42) | ALDH1A1EGFRHDAC3HDAC1HDAC2 | |
| SCHEMBL24038693 | 0.81 | GRM5 (0.39) | — | |
| SCHEMBL1588979 | 0.80 | ALDH1A1 (0.55) | ALDH1A1LMNA | |
| SCHEMBL23360887 | 0.80 | NQO2 (0.41) | ALDH1A1 | |
| SCHEMBL1187384 | 0.77 | ALDH1A1 (0.42) | ALDH1A1RAPGEF4EGFRCES2CES1 | |
| SCHEMBL1189639 | 0.77 | ALDH1A1 (0.54) | ALDH1A1RAPGEF4CA12CA9IDO1 | |
| SCHEMBL13039534 | 0.77 | ALDH1A1 (0.54) | ALDH1A1RAPGEF4CA12CA9IDO1 | |
| SCHEMBL27691414 | 0.75 | ALDH1A1 (0.41) | ALDH1A1LMNA | |
| SCHEMBL16719646 | 0.75 | ALDH1A1 (0.37) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111909083-B | Inhibitors of histone demethylase | 赛尔基因昆蒂赛尔研究公司 | 2023-08-15 | — | — | CN | disclosed |
| EP-3160952-B1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2020-12-02 | — | — | EP | disclosed |
| EP-3741749-A1 | HISTONE DEMETHYLASE INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2020-11-25 | — | — | EP | disclosed |
| EP-3738960-A1 | HISTONE DEMETHYLASE INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2020-11-18 | — | — | EP | disclosed |
| CN-111909083-A | Histone demethylase inhibitors | 赛尔基因昆蒂赛尔研究公司 | 2020-11-10 | — | — | CN | disclosed |
| CN-106660982-B | Histone demethylase inhibitors | 赛尔基因昆蒂赛尔研究公司 | 2020-09-08 | — | — | CN | disclosed |
| EP-3332785-B1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA INC (US) | 2020-05-06 | — | — | EP | disclosed |
| US-10385047-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-08-20 | — | — | US | disclosed |
| US-10106534-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-10-23 | — | — | US | disclosed |
| US-20180251458-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-09-06 | — | — | US | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-7176199-B2 | Aryl-substituted alicyclic compound and medical composition comprising the same | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2007-02-13 | — | — | US | disclosed |
| EP-1678185-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-07-12 | — | — | EP | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | disclosed |
| US-20040106622-A1 | Aryl-substituted alicylic compound and medical composition comprising the same | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2004-06-03 | — | — | US | disclosed |
| EP-1371646-A1 | ARYL-SUBSTITUTED ALICYCLIC COMPOUND AND MEDICAL COMPOSITION COMPRISING THE SAME | Dainippon Pharmaceutical Co., Ltd. (JP) | 2003-12-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180251458-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM6A, KDM1A | ALDH1A1 475/4885RAPGEF4 1596/4885SOS1 2756/4885 |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | ALDH1A1 355/4885RAPGEF4 4025/4885SOS1 768/4885 |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | ALDH1A1 412/4885RAPGEF4 4155/4885SOS1 2442/4885 |
| US-10106534-B2 | Histone demethylase inhibitors | KDM1B, KDM6A, KDM1A | ALDH1A1 475/4885RAPGEF4 1596/4885SOS1 2756/4885 |
| US-10385047-B2 | Histone demethylase inhibitors | KDM1B, KDM6A, KDM1A | ALDH1A1 475/4885RAPGEF4 1596/4885SOS1 2756/4885 |
| US-20040106622-A1 | Aryl-substituted alicylic compound and medical composition comprising the same | ITGB3, ITGB1, ITGAL | ALDH1A1 309/4885RAPGEF4 4599/4885SOS1 4231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.